Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
This was a phase 3, multi-center, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of oral administration of
bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and
inadequate glycemic control.